Implementation of the Track and Trace system for export of Pharmaceuticals and drug consignments along with maintaining the Parent Child relationship in the levels of packaging and their movement in supply chain Extension of date of implementation regarding.

Okay, here's the policy analysis report based on the provided text. **1. Executive Summary:** This report analyzes a public notice issued by the Directorate General of Foreign Trade (DGFT) regarding the implementation of a "Track and Trace" system for pharmaceutical exports. The notice specifically addresses an amendment extending the deadline for implementing the system, which requires maintaining parent-child relationships in packaging levels and uploading data to a central portal, until March 31, 2023. This extension aims to provide more time for both Small Scale Industries (SSI) and non-SSI manufacturers to comply with the requirements. **2. Introduction:** This report provides an overview and analysis of Public Notice No. 01/2015-20, dated April 4, 2022, issued by the Directorate General of Foreign Trade (DGFT), as published in *The Gazette of India*. The report focuses on the content of the provided text to inform about the amendment made to the implementation timeline for the Track and Trace system for pharmaceutical exports. **3. Policy Overview:** * This notice amends Para 2.90A of the Handbook of Procedure 2015-20. * **Core Objective:** The core objective of the original policy (as inferred from the context of the amendment) is to implement a "Track and Trace" system for pharmaceutical exports, specifically to ensure the integrity and traceability of drug formulations through the supply chain. This includes maintaining a "Parent-Child relationship" in the different packaging levels and uploading this information to a central portal. **4. Background and Rationale:** This is an amendment to the existing policy. The amendment likely responds to challenges faced by pharmaceutical manufacturers (both SSI and non-SSI) in fully implementing the Track and Trace system within the initially specified timeframe. The extension suggests that compliance with requirements related to maintaining parent-child packaging relationships and central portal uploads has proven difficult to achieve by the original deadline of April 1, 2022. **5. Key Provisions / Changes:** This public notice introduces a single, but crucial, change: * **Specific Part of Original Policy Changed:** Para 2.90 A vi and vii of Handbook of Procedure 2015-20. * **New Rule/Provision:** The original date of "01.04.2022" is replaced with "31.3.2023". * **Difference/Effect of Change:** This change extends the deadline for implementing the Track and Trace system for export of drug formulations. This extension applies specifically to the requirement of maintaining the Parent-Child relationship in packaging levels and uploading this data to a Central Portal. Manufacturers now have until March 31, 2023, to comply with these aspects of the regulation. **6. Target Audience and Stakeholders:** The primary target audience for this notice is pharmaceutical manufacturers involved in exporting drug formulations from India. This includes both Small Scale Industries (SSI) and non-SSI manufacturers. Other stakeholders include export-related agencies, customs officials, and potentially international regulatory bodies that rely on the integrity of the pharmaceutical supply chain. **7. Implementation Aspects (Inferred):** * **Responsible Agency:** The Directorate General of Foreign Trade (DGFT) is the responsible agency for implementing and overseeing this policy. * **Timelines:** The key timeline aspect is the extended deadline of March 31, 2023, for implementing the Track and Trace system regarding maintaining the Parent-Child relationship in packaging and uploading data to the central portal. * The notice references other public notices, implying the existence of established procedures and guidelines, although not elaborated on within the text. **8. Expected Outcomes / Impact of Changes:** The primary intended outcome of extending the deadline is to facilitate smoother implementation of the Track and Trace system. It is expected that this will allow pharmaceutical manufacturers, particularly those facing initial compliance challenges, sufficient time to adapt their processes, packaging, and data management systems to meet the requirements. This extension should ultimately contribute to a more robust and traceable pharmaceutical export supply chain. Delaying the deadline potentially delays improved tracking capabilities. **9. Conclusion:** Public Notice No. 01/2015-20 provides a crucial amendment to the implementation timeline for the Track and Trace system for pharmaceutical exports. By extending the deadline to March 31, 2023, the DGFT acknowledges the challenges faced by pharmaceutical manufacturers and aims to ensure more comprehensive and effective implementation of this critical system for maintaining the integrity and traceability of exported drugs. This extension is significant for both SSI and non-SSI manufacturers, allowing them more time to adjust to the required changes in packaging and data handling.

Key Entities Referenced